Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ONCO
Onconetix, Inc.
CAPPED RATING
Onconetix, Inc. (ONCO) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (F). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Overall Rating
1.9
/ 5.0
C-
Value
B+
Factor Score
3.5
/ 5.0
Growth
F
Factor Score
0.3
/ 5.0
Profitability
C
Factor Score
2.5
/ 5.0
Momentum
F
Factor Score
0.7
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
0.6
Rev Growth YoY
-83.9%
Gross Margin
80.4%
Price Return 3M
-57.6%
Price Return 12M
-99.8%
Catalyst Signal
0.00
Market Cap
$2.2M
TTM Revenue
$645.8K
Price / Sales
3.3
ROE
-105.2%
Historical Factor Score Progression
Held C- for 5 weeks
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B+ (3.5) | F (0.3) | C (2.5) | F (0.7) | C+ (2.6) | C- (1.9) |
| 2026-11-07 | B+ (3.5) | F (0.2) | C+ (2.5) | D (1.5) | C+ (2.7) | C- (2.1) |
| 2026-10-31 | B+ (3.5) | F (0.2) | C (2.5) | D (1.2) | C+ (2.7) | C- (2.0) |
| 2026-10-24 | B (3.5) | F (0.2) | C (2.5) | D- (0.7) | C+ (2.6) | C- (1.9) |
| 2026-10-17 | B (3.5) | F (0.2) | C (2.5) | D- (0.7) | C+ (2.6) | C- (1.9) |
Page
1
of
4